- |||||||||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Clinical, Journal: Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S-1 as second-line chemotherapy in metastatic pancreatic cancer. (Pubmed Central) - Jun 16, 2021
We retrospectively reviewed 76 consecutive patients with metastatic pancreatic adenocarcinoma who underwent mFOLFIRINOX or S-1 treatment as a second-line chemotherapy after gemcitabine plus nab-paclitaxel (GnP) failure at our department between December 2014 and February 2019...mFOLFIRINOX as a second-line regimen contributed to favorable treatment outcomes, but induced more frequent adverse events than S-1. On multivariate analyses, mFOLFIRINOX was identified as an independent factor with favorable PFS, suggesting that mFOLFIRINOX could be a promising treatment option for patients with GnP failure.
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Pseudomyxoma retroperitonei masquerading as a psoas abscess. (Pubmed Central) - Jun 12, 2021
Our treatment plan after ileostomy was cytoreductive surgery along with adjuvant radiotherapy (40 Gy in 20 fractions) with chemotherapy (5-fluorouracil and folinic acid given for 30 weeks, once a week). However, after ileostomy, the patient refused further treatment, citing financial reasons.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: NCI-2018-00737: Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 11, 2021
P2, N=6, Completed,
However, after ileostomy, the patient refused further treatment, citing financial reasons. Recruiting --> Completed | N=44 --> 6 | Trial completion date: Dec 2035 --> May 2021 | Trial primary completion date: Dec 2035 --> May 2021
- |||||||||| aspirin / Generic mfg.
Clinical, Journal, PD(L)-1 Biomarker, IO biomarker: Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin. (Pubmed Central) - Jun 11, 2021
The aim of this study was to determine the effect of folinic acid, 5-FU and oxaliplatin (FOLFOX) as a single agent and aspirin plus FOLFOX in various combinations on the aforementioned proteins in human CRC, SW480 cell line and rat models of N-Methyl-N-Nitrosourea (NMU)-induced CRC...The mechanistic rational of these effects underscores the importance of expanded concept of possible aspirin combination therapy with FOLFOX sequentially in future CRC management. Validation of our findings through randomized clinical trials of aspirin plus FOLFOX sequentially in patients with CRC is therefore warranted.
- |||||||||| Enrollment open, Trial completion date, Trial primary completion date, Metastases: I-FLOAT: Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies (clinicaltrials.gov) - Jun 10, 2021
P1, N=54, Recruiting,
Validation of our findings through randomized clinical trials of aspirin plus FOLFOX sequentially in patients with CRC is therefore warranted. Not yet recruiting --> Recruiting | Trial completion date: Sep 2025 --> May 2027 | Trial primary completion date: Sep 2023 --> Jun 2022
- |||||||||| irinotecan / Generic mfg.
Clinical, Journal: Association of losartan with outcomes in metastatic pancreatic cancer patients treated with chemotherapy. (Pubmed Central) - Jun 10, 2021
Our findings should be validated in a larger cohort to confirm if the benefit of losartan and FOLFIRINOX seen in a neoadjuvant setting for locally advanced cancer also applies to metastatic cancer. This research adds to growing data on the efficacy of angiotensin receptor blocking drugs as adjunctive treatment in addition to chemotherapy in pancreatic cancer with specific focus on metastatic disease.
- |||||||||| irinotecan / Generic mfg.
Journal: Data Driven Mathematical Model of FOLFIRI Treatment for Colon Cancer. (Pubmed Central) - Jun 3, 2021
For instance, patients in cluster 3 with the highest T-reg/T-helper ratio respond better to the FOLFIRI treatment, while patients in cluster 2 with the lowest T-reg/T-helper ratio resist the treatment. Moreover, we use ROC curve to validate the model using the tumor status of the patients at their follow up, and the model predicts well for the earlier follow up days.
- |||||||||| oxaliplatin / Generic mfg.
Journal: Unexpected Ca-mobilization of oxaliplatin via H1 histamine receptors. (Pubmed Central) - Jun 2, 2021
Last, activation of H1 via either histamine or oxaliplatin activates TRPV1 receptors, a mechanism that has been associated with itch. These data, together with literature data that has shown that anti-histamine agents reduce the incidence of oxaliplatin-induced hypersensitivity, may provide a molecular mechanism of this side effect in oncological patients.
- |||||||||| leucovorin calcium / Generic mfg., sulphadiazine / Generic mfg., pyrimethamine / Generic mfg.
[VIRTUAL] LATE DIAGNOSIS OF CONGENITAL TOXOPLASMOSIS. ¿IS AVIDITY TESTING A RELIABLE TECHNIQUE? () - Jun 2, 2021 - Abstract #ESPID2021ESPID_1400;
Sometimes, low avidity persists longer than 4-6 months, so result interpretation must be rigorous until diagnosis is reached. Toxoplasma serology should be performed in all 3 trimesters of pregnancy in order to diagnose as soon as possible to start treatment and reduce sequelae.
- |||||||||| oxaliplatin / Generic mfg.
[VIRTUAL] Significance of adding oxaliplatin to postoperative adjuvant chemotherapy in elderly patients with colorectal cancer () - Jun 1, 2021 - Abstract #ESMOGI2021ESMO_GI_423;
Methods This retrospective study included patients aged over 70 years who were diagnosed with high-risk stage II and stage III CRC and received postoperative adjuvant oral Fp monotherapy (capecitabine or uracil and tegafur [UFT]+leucovorin [LV]) or Fp+OX (CAPOX or FOLFOX) in our hospital between January 2010 and December 2019...Conclusions Adjuvant chemotherapy with OX for elderly patients was relatively tolerable, and the DFS and OS seemed to be better than the results of the previous trials. However, the benefit of adding OX to Fp in the adjuvant setting was not observed in this study, even though Japan has the highest life expectancy in the world.
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Real-life experience with chemotherapy plus biologics in first-line treatment of right-sided, RAS wild-type, metastatic colon cancer: A multicenter Onco-Colon Turkey study () - Jun 1, 2021 - Abstract #ESMOGI2021ESMO_GI_371;
Four patients treated with triplet chemotherapy backbone (5-fluorouracil, oxaliplatin and irinotecan) were excluded from the analysis...The proportion of patients receiving treatment including panitumumab, cetuximab and bevacizumab was 19%, 27% and 54%, respectively...OS was longer with oxaliplatin (anti-EGFR vs anti-VEGF; 32.8 vs 22.8 mo s) compared to irinotecan (anti-EGFR vs anti-VEGF; 18.8 vs 19.3 mo s) based regimens. Conclusions Anti-EGFR and oxaliplatin based treatment regimens and treatment responders were positive prognostic factors for OS in RAS wild-type mrCC patients.
- |||||||||| cisplatin / Generic mfg., irinotecan / Generic mfg.
[VIRTUAL] Survival comparison of first-line therapies in locally advanced or metastatic pancreatic cancer: A Portuguese oncology unit experience () - Jun 1, 2021 - Abstract #ESMOGI2021ESMO_GI_358;
Data are lacking on the efficacy comparing a regimen combining oxaliplatin (Ox), irinotecan, 5-fluorouracil and leucovorin (FOLFIRINOX) with gemcitabine plus nab-paclitaxel (Gem/Nab) as first-line therapy in patients with LAMPC...For first-line ChT, the majority started with gem/nab (43.9%); FOLFIRINOX (14.6%) or others: gem alone or combined with ox, cisplatin or capecitabine (CAP)(41.5%)...Despite small variances in mPFS, mOS is similar in both groups. It is mandatory to develop further studies on therapeutic sequencing with real-life data with the main goal of improving PFS and OS, and maintaining quality of life.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Primary tumour location and efficacy of first-line anti-EGFR agents in the treatment of RAS wild-type metastatic colorectal cancer () - Jun 1, 2021 - Abstract #ESMOGI2021ESMO_GI_355;
A doublet chemotherapy plus anti-EFGR was used in 98% of patients (77% cetuximab and 21% panitumumab)...The small number of patients with R disease and short follow-up may have limited conclusions on anti-EGFR s as a first-line approach according to tumour sidedness. Future prospective studies are needed, as the majority of data comes from retrospective analyses, that might also address the possible mechanisms of resistance to anti-EGFR therapy in R-sided RAS wt mCRC.
- |||||||||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
[VIRTUAL] Safety and feasibility of liposomal irinotecan for unresectable pancreatic adenocarcinoma: Real-world experience in a Japanese cohort () - Jun 1, 2021 - Abstract #ESMOGI2021ESMO_GI_342;
Background Liposomal irinotecan (nal-IRI), which was shown to have survival benefits for patients with gemcitabine-refractory metastatic pancreatic ductal adenocarcinoma (PDAC) in the NAPOLI-1 trial, was approved in combination with 5-fluorouracil/leucovorin (5-FU/LV) in June 2020 in Japan...An 81-year-old female patient with pancreatic head cancer and multiple liver metastases received nal-IRI regimen as second-line chemotherapy after gemcitabine + nab-paclitaxel therapy...Conclusions This study confirmed the partial therapeutic benefit of nal-IRI + 5-FU/LV treatment with an acceptable toxicity profile in a Japanese cohort. Our experience supports the claim that this regimen could serve as standard treatment, even in the elderly, after the failure of first-line gemcitabine-based treatment in patients with unresectable PDAC in real-world clinical settings.
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
[VIRTUAL] Does metastasectomy really improve survival in gastric cancer? () - Jun 1, 2021 - Abstract #ESMOGI2021ESMO_GI_324;
Conclusions Metastasectomy in gastric/gastroesophageal junction cancer was associated with improved overall survival, even when compared to a matched-paired population of metastatic patients with a favorable prognostic profile. This study reinforces the importance of considering this approach, when reasonable, for mG/GEJC patients.
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
[VIRTUAL] External validation of prognostic ALAN score in patients with inoperable bile duct cancer treated with second-line chemotherapy () - Jun 1, 2021 - Abstract #ESMOGI2021ESMO_GI_284;
Conclusions Second-line treatment can be a potentially useful option for a few patients with bile duct cancer; our analysis suggests that ALAN score might be used in this setting for patient survival estimates, helping treatment decisions. In addition, a simplified version of ALAN score, comprised only of serum albumin levels and neutrophil count, might be used instead as it was able to define patient prognosis more accurately compared to the standard ALAN score.
- |||||||||| epirubicin / Generic mfg.
[VIRTUAL] Risk of nausea and vomiting in a real-world data cohort of chemotherapy-treated patients with metastatic gastric or gastroesophageal junction adenocarcinoma by medical history of gastrectomy () - Jun 1, 2021 - Abstract #ESMOGI2021ESMO_GI_257;
Zolbetuximab, an IgG1 monoclonal antibody, is being evaluated with chemotherapy for the treatment of advanced gastric or gastroesophageal junction (G/GEJ) cancer...Common chemotherapy regimens were fluorouracil leucovorin calcium oxaliplatin (25.3%), fluorouracil leucovorin calcium (17.5%), fluorouracil (13.3%), capecitabine (13.1%), capecitabine-epirubicin-oxaliplatin (7.2%), and fluorouracil-oxaliplatin (3.5%)...Conclusions These results suggest prior gastrectomy is not associated with a different risk of nausea and vomiting in patients with metastatic G/GEJ cancer treated with first-line chemotherapy. This study, which utilized real-world data, expands the understanding of gastrectomy as a risk factor for nausea and vomiting in this study population.
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Circulating RNA detection, circulating tumor cells count, and molecular tumor profiling in a cohort of untreated metastatic colorectal cancer: A prospective multicenter ancillary study to the randomized VISNÚ trials () - Jun 1, 2021 - Abstract #ESMOGI2021ESMO_GI_252;
Methods A total of 151 patients (p) screened in 11 Spanish hospitals for inclusion in the VISN -1 (FOLFIRINOX/bevacizumab vs. FOLFOX/bevacizumab) and VISN -2 (FOLFIRI/bevacizumab vs. FOLFIRI/cetuximab; RAS-wildtype) trials were analyzed for circulating mRNA (ADAR1, PD-L1, AGR2, LGR5, DCLK1, CK20, HPRT1 and 18S) and mature microRNA (n=17) expression profile, tumor RAS/BRAF/PI3KA sequenced variants, and baseline circulating tumor cell (bCTC) count...Conclusions Our study has demonstrated the feasibility of the integrated use of CTCs, mRNA, and miRNAs as biomarkers of mCRC in multicenter prospective studies. Liquid biopsy based on RNA markers can provide real-time monitoring of tumor heterogeneity and theoretically, improve CRC clinical staging, and prognostic stratification.
- |||||||||| Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
[VIRTUAL] The impact of first-line chemotherapy in elderly patients with advanced pancreatic cancer: A mono-institutional retrospective study () - Jun 1, 2021 - Abstract #ESMOGI2021ESMO_GI_227;
The majority of pts received gemcitabine nab-paclitaxel (60%), other regimes included gemcitabine (28%), FOLFIRINOX (5%), capecitabine (4%), FOLFOX (2%) and FOLFIRI (1%)...On the basis of our results, the baseline ECOG PS can be considered a prognostic factor for both PFS and OS. In conclusion, elderly pts should not be precluded from active treatment, and careful patient selection, mainly according to baseline ECOG PS, should guide treatment indication.
- |||||||||| Avastin (bevacizumab) / Roche
[VIRTUAL] The role of site of metastatic resection in metastatic colorectal cancer patients: A mono-institutional cohort study () - Jun 1, 2021 - Abstract #ESMOGI2021ESMO_GI_226;
The following variables were collected: age (> vs 65 years); gender (male vs female); primary tumor site (right vs left); synchronous vs metachronous; RAS/BRAF status; number (N) of MR (1, 2 or 3); chemotherapy treatment (No treatment vs Post-operative vs Peri-operative/pre-operative treatment) and chemotherapy regimen (5FU monotherapy, oxaliplatin-based, irinotecan-based regimen, FOLFOXIRI, bevacizumab, anti-EGFR)...Based on our analysis, a higher number of MR is associated with long-term survival, and this could be explained with an accurate selection of patients that could benefit from multiple radical resections. Thus, a multidisciplinary approach is essential for the management of mCRC pts and surgery should be evaluated case by case and always performed when possible, even several times, independently of site of MR.
- |||||||||| adagrasib (MRTX849) / Mirati, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation () - Jun 1, 2021 - Abstract #ESMOGI2021ESMO_GI_224;
P3
Methods KRYSTAL-10 (NCT04793958) is a global, open-label, randomized Phase 3 study evaluating the efficacy and safety of adagrasib (600 mg BID) in combination with cetuximab (500 mg/m2 Q2W) vs chemotherapy in pts with CRC harboring a KRAS G12C mutation who have progressed on or after treatment with a standard first-line fluoropyrimidine-based chemotherapy regimen containing either oxaliplatin or irinotecan...Approximately 420 pts will be randomized 1:1 to receive adagrasib in combination with cetuximab or chemotherapy. Randomization will be stratified by region (United States/Canada vs all other countries) and time to disease progression after beginning first-line treatment (This study will be enrolling at sites in North America, South America, Europe, Asia, and Australia.
|
